Prolonged Clinical Follow-up of OPTIMA-5

Exclusion Criteria

• •1. Cardiogenic shock;
• •2. Active bleeding or at high risk of bleeding (including grade Ⅲ or Ⅳ retinopathy or retinal gastrointestinal or urinary tract hemorrhage within the past 1 month);
• •3. Ischemic stroke or TIA in the past 6 months;
• •4. History of hemorrhagic stroke;
• •5. Platelet count \<100×109/L or hemoglobin \<100 g/L;
• •6. Known intracranial aneurysm;
• •7. Severe trauma, surgery or head injury within 1 month;
• •8. Suspected aortic dissection or infective endocarditis;
• •9. Recent puncture with difficult hemostasis by compression (eg, visceral biopsy, compartment puncture);
• •10. Currently taking anticoagulants;
• •11. Poorly controlled hypertension ( ≥180/110 mmHg);
• •12. Hepatic or renal impairment (glutamic-pyruvic transaminase, glutamic oxalacetic transaminase, or γ -glutamyl transferase \>2.5 times upper limit of normal value; creatinine \>1.5 times upper limit of normal value);
• •13. Known allergy to r-SAK;
• •14. Pregnancy, lactation, or planning for pregnancy;
• •15. History of myocardial infarction or CABG;
• •16. Having taken antiplatelet drugs other than aspirin and ticagrelor, such as clopidogrel, prasugrel or cilostazol after the symptom onset;
• •17. Patients with other conditions that made them unsuitable to be recruited at the discretion of the investigators.
• •1. Patients who had received r-SAK thrombolytic therapy before;
• •2. Previous diagnosis of Staphylococcus aureus infection;
• •3. Patients who were participating in other clinical trials;
• •4. Other patients considered unsuitable for inclusion by the investigators.